An experimental pill to treat Covid developed by the US company Pfizer cuts the risk of hospitalisation or death by 89% in vulnerable adults, clinical trial results suggest. The drug - Paxlovid - is intended for use soon after symptoms develop in people at high risk of severe disease. . . . . Interim data from trials of the treatment in 1,219 high-risk patients who had recently been infected with Covid found that 0.8% of those given Paxlovid were hospitalised compared with 7% of patients who were given a placebo or dummy pill. They were treated within three days of...